Paxman launches neuropathy system to target chemotherapy nerve damage

Paxman has launched its Neuropathy System to help reduce chemotherapy-induced peripheral neuropathy, a common side effect that can cause lasting nerve damage and disrupt cancer treatment. The rollout is supported by clinical data and will begin in several European markets after recent regulatory approvals.

Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, affects millions of cancer patients worldwide each year. - CIPN can cause numbness, pain, tingling and loss of sensation in the hands and feet. - The condition can reduce quality of life and force chemotherapy dose reductions, delays or discontinuation. - Paxman’s new system targets a major unmet need because no established standard preventive therapy exists for CIPN.

What happened: - Paxman announced the launch of the Paxman Neuropathy System, a cryocompression device designed to reduce the risk and severity of CIPN. - The company said the launch marks its first major product expansion beyond scalp cooling for chemotherapy-related hair loss. - Paxman is based in Huddersfield, West Yorkshire, United Kingdom. - The company has been a global leader in scalp cooling for more than 25 years, a position strengthened by its 2025 acquisition of Dignitana.

The details: - The Paxman Neuropathy System uses cryocompression technology to manage chemotherapy side effects. - The company said the technology could help more patients continue prescribed treatment regimens. - The launch coincides with clinical data from a prospective multicenter Phase I/II study published in JCO Oncology Advances. - The study evaluated the device in patients receiving taxane-based chemotherapy. - Researchers found the device was safe and well tolerated and was associated with low rates of CIPN. - Among 146 evaluable patients, no participant developed severe neuropathy. - Patient-reported clinically significant sensory symptoms remained low throughout follow-up. - The launch also coincides with a scientific review in Therapeutic Advances in Medical Oncology on the causes, effects and prevention of CIPN. - The review highlighted CIPN’s burden on patients and health systems and identified cryotherapy and cryocompression as promising interventions.

Between the lines: - Paxman is expanding from one treatment-related side effect into another, signaling a broader strategy in oncology supportive care. - The new product gives Paxman a way to leverage its existing cooling expertise in a different clinical setting. - The clinical publications help position cryocompression as a prevention strategy rather than only a symptom-management tool. - Ongoing studies in the U.S. and at Dana-Farber Cancer Institute suggest the evidence base is still developing, even as commercialization begins.

What's next: - The Paxman Neuropathy System will launch in the United Kingdom, France, Germany, the Netherlands, Spain and Italy following recent regulatory approvals. - Pilot programs are already running in the U.K. - Paxman expects to expand to additional centers across Europe in the coming months. - The technology is also being studied in the ongoing randomized SWOG-S2205-ICE-COMPRESS trial in the U.S. and in a separate clinical study at Dana-Farber Cancer Institute.

The bottom line: - Paxman is betting that its cooling technology can move beyond hair loss and into a larger cancer-supportive care market with few established preventive options.